Clinical Trials Logo

Clinical Trial Summary

This study aims to study prospectively the clinical and paraclinical evolution and prognostic factors of autoimmune haemolytic anemias, Evans syndromes and chronic immunological thrombocytopenic purpura of children in France.


Clinical Trial Description

These autoimmune haematological diseases are rare diseases affecting the child, often very young, and serious and potentially life-threatening. International literature data are scarce, and include individual cases or small series.

They do not allow to determine an optimal therapeutic strategy in case of escape from the first-line treatments. Existing treatments (long-term corticosteroid therapy, immunoglobulins, splenectomy, immunosuppressants, chemotherapies, and more recently anti-CD20 antibodies) are inconsistently effective, and often associated with serious side effects.

The seriousness of these diseases, the therapeutic difficulties, and the absence of a targeted research project in France, led to the implementation of this study.

This study aims to study prospectively the clinical and paraclinical evolution and prognostic factors of autoimmune haemolytic anemias, Evans syndromes and chronic immunological thrombocytopenic purpura of children in France. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04070612
Study type Observational
Source University Hospital, Bordeaux
Contact
Status Completed
Phase
Start date April 4, 2007
Completion date June 8, 2012

See also
  Status Clinical Trial Phase
Completed NCT02104440 - Clinical Trial In The Treatment Of Allogeneic Post-Transplant Cytopenias With Sequential Infusion Of Allogeneic Mesenchymal Cells Expanded In Vitro Phase 2
Active, not recruiting NCT03682029 - Epigenetics, Vitamin C, and Abnormal Blood Cell Formation - Vitamin C in Patients With Low-Risk Myeloid Malignancies N/A
Recruiting NCT03026751 - Improving Diagnosis in Idiopathic Cytopenia Using Gene Sequencing N/A
Recruiting NCT06430788 - A Study of Emapalumab for Pediatric Aplastic Anemia Phase 2
Recruiting NCT04873102 - Danazol for Treatment of Cytopenias in Patients With Cirrhosis Phase 2
Not yet recruiting NCT06285825 - A Pilot Study of Emapalumab for the Treatment of CAR T-Cell Therapy-Associated Prolonged Cytopenia Early Phase 1
Active, not recruiting NCT06276036 - Autoimmune Cytopenias as a Sign of Primary Immunodeficiency. N/A
Terminated NCT03733249 - Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study Phase 1/Phase 2
Recruiting NCT02958462 - Pre-myeloid Cancer and Bone Marrow Failure Clinic Study N/A
Recruiting NCT05236764 - Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion N/A
Recruiting NCT04741945 - Repurposing Metformin as a Leukemia-preventive Drug in CCUS and LR-MDS Phase 2
Completed NCT01928537 - Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine Phase 3
Recruiting NCT04419649 - A Study of KER-050 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes Phase 2
Active, not recruiting NCT03301168 - Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant Phase 1/Phase 2
Terminated NCT02065869 - Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant Phase 1/Phase 2
Completed NCT00367588 - Low Bacterial Diet in Patients With Cytopenia N/A